title: [Pre-pregnancy and early clinical analysis of TORCH infections detection].
abstract: OBJECTIVE
  For the birth, to improve the quality of the population, to explore the prevention and treatment of early pregnancy TORCH infection, and treatment of patients with positive eugenics and guidance.
  
  
  METHODS
  Enzyme-linked immunosorbent assay (ELISA) testing of all the objects in the peripheral blood-money pathogen-specific antibodies LgM. Person in charge of testing. In strict accordance with the instructions. Reagents from Shanghai magnolia biotechnology institute.
  
  
  RESULTS
  The total number of 319 cases of positive, with a total infection rate: 3.28%, TOX-IgM, RV-IgM, CMV-IgM, HSV (II)-IgM infection rate of 0.103 percent, 2.64 percent and 0.309 percent, 0.237 percent; 319 cases of TORCH infected persons are to receive treatment for the treatment of wrap, with a total negative rate of 97.49 percent.
  
  
  CONCLUSIONS
  Detection of TORCH infections to ensure early diagnosis, early treatment and early prevention is necessary.
authors.affiliation: Family Planning Service Station of Yan Cheng County, Shandong Province 276100, China.
authors.forename: Ai-Hua
authors.initials: AH
authors.lastname: Fu
mesh_terms: D000913:Antibodies, Protozoan / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology* / Q000302:isolation & purification; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology* / Q000821:virology*; D012412:Rubella virus / Q000187:drug effects / Q000276:immunology* / Q000302:isolation & purification; D018139:Simplexvirus / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification*; D014122:Toxoplasma / Q000187:drug effects / Q000276:immunology* / Q000302:isolation & purification; D016896:Treatment Outcome
chemical_list: D000913:Antibodies, Protozoan; D000914:Antibodies, Viral; D000981:Antiprotozoal Agents; D000998:Antiviral Agents; D007075:Immunoglobulin M